CEP-14083 is a potent ATP-competitive ALK kinase inhibitor with an IC50 of 2 nM in enzymatic assays; it also inhibits other kinases such as insulin receptor (IR), vascular endothelial growth factor receptor 2 (VEGFR2/KDR/Flk-1), angiopoietin-1 receptor (TIE2), and dual leucine zipper kinase (DLK); it suppresses CD274 mRNA expression and NPM/ALK function in NPM/ALK-positive T-cell lymphoma (ALK+ TCL) cells; it shows potential for research in lymphoma.